BPC-157 Compounding Legal Status: What Patients and Prescribers Need to Know

What Is BPC-157 and Where Does It Come From?

BPC-157 (body protection compound-157) is a synthetic 15-amino-acid peptide derived from a partial sequence of a protein isolated from human gastric juice. Researchers at the University of Zagreb, led by Predrag Sikiric, have studied it in animal models since the early 1990s. The compound carries no approved drug application in the United States, the European Union, or any major regulatory jurisdiction.

Chemical Identity

The full chemical name is L-Val-L-Lys-L-Ala-L-Ala-L-Gly-L-Glu-L-Ala-L-Gly-L-Leu-L-Gly-L-Asp-L-Glu-L-Ser-OH. Its CAS registry number is 137525-51-0. It is not listed in the FDA's Orange Book (Approved Drug Products with Therapeutic Equivalence Evaluations) and has no entry in Drugs@FDA because no sponsor has ever submitted, let alone received approval for, a New Drug Application (NDA) or Biologics License Application (BLA) for this compound. The FDA Orange Book is searchable at accessdata.fda.gov.

Proposed Mechanisms in Animal Models

Preclinical work, most extensively summarized by Sikiric et al. (J Physiol Pharmacol, 2018), describes BPC-157 as interacting with the nitric oxide system, growth hormone receptors, and several inflammatory cytokine pathways in rodents. The same paper reports accelerated tendon-to-bone healing and reduced gastric ulcer formation in rat models. These results are hypothesis-generating, not practice-changing. No human pharmacokinetic data exist to confirm that oral or injectable BPC-157 reaches therapeutic concentrations in human tissue.

FDA Regulatory Status: The Core Legal Question

BPC-157 is not FDA-approved, and since 2023 it may not be legally compounded for individual patients under the 503A pathway. This is the single most consequential regulatory fact for any patient or prescriber evaluating this compound.

Section 503A of the Federal Food, Drug, and Cosmetic Act

Section 503A governs compounding pharmacies that prepare medications for specific, identified patients based on a valid prescription. Under 503A, pharmacies may compound drugs that are not commercially available, but only if the active pharmaceutical ingredient (API) is not on the FDA's "Difficult to Compound" or "Do Not Compound" lists. The FDA maintains its current 503A lists at fda.gov.

In its 2023 guidance cycle, FDA formally added BPC-157 to the category of bulk drug substances that present safety risks sufficient to prohibit 503A compounding. The agency's reasoning: no adequate evidence of safety or effectiveness in humans, no accepted clinical use, and no pharmacopeial monograph. FDA's compounding guidance documents are available at fda.gov.

Section 503B Outsourcing Facilities

Section 503B outsourcing facilities operate under different rules and may produce larger batches without patient-specific prescriptions. BPC-157 is equally prohibited under 503B because it does not appear on the FDA's 503B bulks list of permitted substances. The 503B bulks list is maintained at fda.gov.

What "Prohibited" Means in Practice

A pharmacy that continues to compound BPC-157 after the final rule is operating outside federal law. Products sold online as "research chemicals" or "not for human use" occupy a legal gray area, but consumers who purchase and self-administer such products receive no FDA oversight of purity, sterility, potency, or identity. FDA's guidance on unapproved drugs is at fda.gov.

Has BPC-157 Ever Been FDA Approved?

No. Not for any indication, at any dose, in any route of administration. The question comes up frequently because some telehealth and wellness marketing has used language that implies legitimacy.

No IND, No NDA, No Phase I Data

A drug reaches approval only after an Investigational New Drug (IND) application, Phase I safety trials, Phase II proof-of-concept trials, and Phase III efficacy trials. As of January 2025, no sponsor has an active IND for BPC-157 registered in ClinicalTrials.gov. ClinicalTrials.gov is searchable at clinicaltrials.gov. No Phase I dose-escalation study in humans has been published. The compound has skipped every step of the standard drug-development pathway on the way to consumer use.

The EMA Situation

The European Medicines Agency (EMA) similarly has no approved product containing BPC-157. There is no EPAR (European Public Assessment Report) for the compound. EMA product information is searchable at ema.europa.eu. This means the compound lacks regulatory approval across both major Western drug-approval systems.

What Does the Evidence Actually Show?

The honest answer is: a meaningful signal in animal models and essentially no human data. Advocates often present the animal literature as though it is directly translatable; it is not.

Preclinical Data: Tendon, Gut, and CNS

Sikiric et al. (J Physiol Pharmacol, 2018; PMID 30025208) compiled decades of Zagreb group data showing that systemic BPC-157 at doses of 10 mcg/kg to 10 mg/kg accelerated healing of Achilles tendon transections, reduced indomethacin-induced gastric ulcers, and attenuated dopaminergic lesion effects in rats. The authors describe a "stable gastric pentadecapeptide" with a "unique healing and cytoprotection activity."

These are legitimate preclinical findings. The problem is the translational gap. Rats and humans differ substantially in peptide metabolism, blood-brain barrier permeability, and gastric acid environment. A compound that survives gastric passage in a rat model may degrade entirely before reaching systemic circulation in a human.

The Absence of Human Pharmacokinetic Data

No published study has measured plasma BPC-157 concentrations in humans after oral dosing. No published study has established the half-life, volume of distribution, or renal clearance of BPC-157 in any human subject. The NIH National Library of Medicine's PubMed database shows no human PK trials as of this writing. Without this data, dosing recommendations circulating online are entirely speculative.

Reported Adverse Effects in Animal Models

At very high doses in rodents, BPC-157 has been associated with transient hypotension and altered platelet aggregation. A 2019 review in Current Pharmaceutical Design catalogued cardiovascular signals in animal models. Whether these effects scale to humans is unknown.

The table below summarizes the evidence hierarchy for BPC-157 compared to a standard approved peptide drug (semaglutide) to give prescribers a concrete reference frame.

| Evidence Level | BPC-157 | Semaglutide (approved) | |---|---|---| | Phase I human safety | None | Completed | | Phase II proof-of-concept | None | Completed | | Phase III RCT | None | STEP-1 (N=1,961) and others | | FDA NDA/BLA approval | No | Yes (Ozempic 2017, Wegovy 2021) | | Compounding status | Prohibited (503A/503B) | Permitted under shortage rules | | Published human PK data | None | Extensive |

BPC-157 Safety: What Is and Is Not Known

The FDA's position that BPC-157 presents unknown safety risks is not speculative. It reflects the regulatory standard that any substance administered to humans should first demonstrate safety in Phase I trials.

Contamination Risk in Unregulated Products

Products labeled "BPC-157" sold through research chemical suppliers or overseas pharmacies are not manufactured under FDA Current Good Manufacturing Practice (cGMP) standards. FDA cGMP requirements are outlined at fda.gov. Independent testing of peptide products in this category has found variable purity, bacterial endotoxin contamination, and in some cases complete absence of the labeled active ingredient. Injecting a contaminated product carries risk of local abscess, septicemia, and systemic inflammatory response.

Injection Site Reactions

Because no formal safety database exists, the frequency of injection site reactions is unknown. Anecdotal reports on patient forums describe erythema, induration, and pain at subcutaneous injection sites. Without a controlled safety study, it is impossible to determine whether these reactions are attributable to BPC-157 itself, excipients, or contaminants.

Drug Interaction Data

No formal drug-drug interaction studies have been conducted in humans. BPC-157's proposed nitric oxide modulation could theoretically potentiate the effects of phosphodiesterase inhibitors or nitrate-based vasodilators. Nitric oxide pathway interactions are reviewed in a 2018 paper by Sikiric et al. Whether this represents a clinically meaningful interaction in humans remains untested.

Population-Specific Risks

Pregnant patients, pediatric patients, and patients with renal or hepatic impairment have no safety data whatsoever. The FDA's prohibition on compounding effectively removes any supervised clinical pathway through which such data could be gathered for individual patients.

The 503A Prohibition: Practical Consequences for Prescribers

A prescriber who writes a prescription for BPC-157 after the 2023 prohibition is asking a pharmacy to fill a prescription for an illegal compound. This carries professional and legal risk.

Prescriber Liability

State medical boards increasingly reference FDA compounding law in enforcement actions. A prescriber cannot rely on a pharmacy's compliance as a shield if the underlying prescription directs compounding of a prohibited substance. State medical board standards often mirror federal FDA guidelines on compounding; see fda.gov for federal reference.

What Pharmacies Must Do

A 503A pharmacy that receives a BPC-157 prescription after the prohibition took effect must decline to fill it. A pharmacy that fills such a prescription risks FDA Warning Letters, injunctions, and referral for criminal prosecution. FDA enforcement actions related to compounding are documented at fda.gov.

Telemedicine Platforms and BPC-157

Several direct-to-consumer telehealth platforms continued offering BPC-157 prescriptions after the 2023 rule. FDA has sent Warning Letters to some of these operators. Patients who receive such prescriptions from online platforms should be aware that the dispensing pharmacy, if it fills the order, is operating outside federal law. FDA Warning Letters are publicly listed at fda.gov.

What Alternatives Exist for Patients Seeking Tissue Repair or Anti-Inflammatory Peptides?

Patients who were using BPC-157 for musculoskeletal recovery, gastrointestinal protection, or general "cytoprotection" should discuss evidence-based alternatives with a qualified clinician.

For Musculoskeletal Recovery

A 2020 Cochrane review of platelet-rich plasma for Achilles tendinopathy (DOI 10.1002/14651858.CD011946.pub2) found limited but emerging evidence for PRP injections, which are performed under physician supervision with regulated biologics. Physical therapy with eccentric loading protocols has Level I evidence for tendinopathy. These options carry known safety profiles.

For GI Mucosal Protection

Proton pump inhibitors such as omeprazole (20 to 40 mg daily) have extensive human safety and efficacy data for peptic ulcer disease and GERD. A meta-analysis published in Alimentary Pharmacology and Therapeutics found PPIs reduced ulcer recurrence by 79% vs. Placebo. Misoprostol and sucralfate are additional FDA-approved options with defined pharmacology.

For Systemic Inflammation

Anti-inflammatory strategies with human evidence include omega-3 supplementation at 2 to 4 g/day EPA+DHA, which reduced high-sensitivity CRP by approximately 0.3 mg/L in a 2022 meta-analysis of 13 RCTs. That meta-analysis is indexed at PubMed. Low-dose naltrexone (1.5 to 4.5 mg nightly) is an off-label option some clinicians use; it carries a defined human safety profile from its approved 50 mg indication.

Monitoring the Regulatory Field Going Forward

The FDA's position on BPC-157 could change if a sponsor submits an IND and completes Phase I trials demonstrating acceptable safety in humans. The Zagreb research group has repeatedly called for clinical trials. As of January 2025, none have been initiated or registered.

How to Track Changes

Clinicians and patients can monitor the FDA's 503A bulks list for any updates at fda.gov. If BPC-157 were ever added to the permitted bulks list, it would signal that the FDA found sufficient evidence of safety to allow supervised compounding. That has not occurred.

The Research Gap

The NIH Reporter database shows no active NIH-funded grants for human BPC-157 trials as of January 2025. The private-sector investment needed to move BPC-157 through IND-to-NDA has not materialized, likely because the compound cannot be patent-protected as a naturally derived peptide sequence.